Lv1
50 积分 2025-09-27 加入
SGLT2 inhibitors protect against diabetic cardiomyopathy and atrial fibrillation through a CaMKII independent mechanism
4天前
已关闭
SGLT2 inhibitors protect against diabetic cardiomyopathy and atrial fibrillation through a CaMKII independent mechanism
5天前
已关闭
Efficacy and Safety of SGLT‐2 Inhibitors in Acute Myocardial Infarction: A Systematic Review and Meta‐Analysis
1个月前
已完结
钠-葡萄糖共转运蛋白-2抑制剂的药理学与临床评价
1个月前
已完结
Interaction between SGLT2 and the sympathetic nervous system in normal and various cardiovascular metabolic disease states
1个月前
已完结
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor
1个月前
已完结
Erratum to “SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF‐2α signaling pathway in arrhythmogenic cardiomyopathy”
1个月前
已完结
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
1个月前
已完结
Effects of sodium‐glucose cotransporter‐2 inhibitors in myocardial infarction patients: A systematic review and meta‐analysis
1个月前
已完结
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial
1个月前
已完结
皖公网安备34019202002308
